[24] Although glutamine is metabolized to glutamate and ammonia, both of which have neurological effects, their concentrations are not increased much, and no adverse neurological effects were detected
We identified key regions in the p53 transactivation domain (TAD) involved in FOXO4 binding and designed an optimized peptide inhibitor (CPP-CAND) with improved cell permeability
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
That said, the following protocols represent standard evidence-informed starting points used in clinical settings